Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting Activating Transcription Factor 3 by Galectin-9 Induces Apoptosis and Overcomes Various Types of Treatment Resistance in Chronic Myelogenous Leukemia

22 Jun 2010

Abstract excerpt

Tyrosine kinase inhibitors (TKI) against Bcr-Abl are the first-line therapeutics for chronic myelogenous leukemia (CML). However, the resistance to Bcr-Abl TKIs is induced in leukemic cells not only by loss of sensitivity to TKIs through Bcr-Abl-related molecular mechanisms but also by loss of addiction to Bcr-Abl TK activity by acquiring Bcr-Abl-unrelated additional oncogenic mutations. Therefore, the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Galectins and Cancer Biology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20571063
DOI: 10.1158/1541-7786.mcr-10-0040

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting Activating Transcription Factor 3 by Galectin-9 Induces Apoptosis and Overcomes Various Types of Treatment Resistance in Chronic Myelogenous LeukemiaPMID 20571063Read ↗

Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways.Semantic proximity Read ↗

Clinical significance of galectin-3 in patients with adult acute myeloid leukemia: a retrospective cohort study with long-term follow-up and formulation of risk scoring system.Semantic proximity Read ↗

Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations.Semantic proximity Read ↗

Extracellular galectin-3 programs multidrug resistance through Na+/K+-ATPase and P-glycoprotein signaling.Semantic proximity Read ↗

Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis.Semantic proximity Read ↗

ATF3, an HTLV-1 bZip factor binding protein, promotes proliferation of adult T-cell leukemia cellsSemantic proximity Read ↗

Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest.Semantic proximity Read ↗

On the role of galectin-3 in cancer apoptosisSemantic proximity Read ↗

G-CSF Upregulates the Expression of Aquaporin-9 through CEBPB to Enhance the Cytotoxic Activity of Arsenic Trioxide to Acute Myeloid Leukemia CellsSemantic proximity Read ↗

Inducing apoptosis in chemotherapy‐resistant B‐lineage acute lymphoblastic leukaemia cells by targeting HSPA5, a master regulator of the anti‐apoptotic unfolded protein response signalling networkSemantic proximity Read ↗

Galectin-3: A novel substrate for c-Abl kinase.Semantic proximity Read ↗

Inhibition of FLT3 Expression by Green Tea Catechins in FLT3 Mutated-AML CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.